AstraZeneca/Merck come out of ASCO GU with a big win over J&J in battle over prostate cancer franchises
The ASCO GU conference has been spotlighting some key advances — and setbacks — for some of the top cancer drugs on the market.
At the top …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
